Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma

Autor: Tsunekazu Mizushima, Hiroyuki Ogawa, Yuriko Otake, Yorihide Okuda, Aya Sugimoto, Yuko Sakakibara, Eiichi Morii, Kazuo Kinoshita, Takahiro Amano, Takashi Kizu, Hidekazu Takahashi, Motohiro Hirao, Shinichiro Shinzaki, Satoshi Egawa, Satoshi Hiyama, Mizuki Tani, Tetsuo Takehara, Manabu Araki, Shinjiro Yamaguchi, Yoshiki Tsujii, Shuko Iwatani, Taku Tashiro, Hideki Iijima, Koji Nagaike, Takahiro Inoue, Masato Komori, Yoshito Hayashi, Jun Murata, Takeo Yoshihara
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
Vascular Endothelial Growth Factor A
Cancer Research
medicine.medical_specialty
Duodenal and jejunal adenocarcinoma
Bevacizumab
Organoplatinum Compounds
genetic structures
medicine.medical_treatment
Leucovorin
Ileal adenocarcinoma
Adenocarcinoma
Gastroenterology
VEGF-A
Surgical oncology
Duodenal Neoplasms
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Genetics
Biomarkers
Tumor
Medicine
Humans
RC254-282
Capecitabine
Aged
Retrospective Studies
Chemotherapy
Small bowel adenocarcinoma
Jejunal Neoplasms
business.industry
Research
Hazard ratio
Immunohistochemical expressions
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Prognosis
Immunohistochemistry
Survival Rate
Vascular endothelial growth factor A
Oncology
Jejunal adenocarcinoma
Biomarker (medicine)
Female
business
medicine.drug
Follow-Up Studies
Zdroj: BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
ISSN: 1471-2407
Popis: Background The efficacy and safety of bevacizumab-containing chemotherapy for patients with metastatic duodenal and jejunal adenocarcinoma (mDJA) are unclear. The present study aimed to evaluate the efficacy of bevacizumab and to explore immunohistochemical markers that can predict the efficacy of bevacizumab for patients with mDJA. Methods This multicentre study included patients with histologically confirmed small bowel adenocarcinoma who received palliative chemotherapy from 2008 to 2017 at 15 hospitals. Immunostaining was performed for vascular endothelial growth factor-A (VEGF-A), TP53, Ki67, β-catenin, CD10, MUC2, MUC5AC, MUC6, and mismatch repair proteins. Results A total of 74 patients were enrolled, including 65 patients with mDJA and 9 with metastatic ileal adenocarcinoma. Patients with mDJA who received platinum-based chemotherapy with bevacizumab as first-line treatment tended to have a longer progression-free survival and overall survival than those treated without bevacizumab (P = 0.075 and 0.077, respectively). Multivariate analysis extracted high VEGF-A expression as a factor prolonging progression-free survival (hazard ratio: 0.52, 95% confidence interval: 0.30–0.91). In mDJA patients with high VEGF-A expression, those who received platinum-based chemotherapy with bevacizumab as a first-line treatment had significantly longer progression-free survival and tended to have longer overall survival than those treated without bevacizumab (P = 0.025 and P = 0.056, respectively), whereas no differences were observed in mDJA patients with low VEGF-A expression. Conclusion Immunohistochemical expression of VEGF-A is a potentially useful biomarker for predicting the efficacy of bevacizumab-containing chemotherapy for patients with mDJA.
Databáze: OpenAIRE
Externí odkaz: